PR Newswire | Jan 18, 2022 07:01AM EST

Clinical Oncology Gastrointestinal Cancers Symposium

01/18 06:00 CST

Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium DUBLIN, Jan. 18, 2022

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data related to advanced GI cancers from ARTISTRY-1, a phase 1/2 study evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA(r)), and preclinical data from the study of nemvaleukin in combination with novel agents in GI cancers.

Details of the presentation are as follows:Abstract: 659Title: Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: preclinical evidence and clinical data from the ARTISTRY-1 trialPresenter: Ulka N. Vaishampayan, M.D., Professor, Internal Medicine, Division of Hematology/Oncology, University of MichiganPresentation Date:The poster, along with a pre-recorded presentation, will be available on the ASCO GI virtual meeting platform beginning Jan. 20, 2022.

About Nemvaleukin Alfa ("nemvaleukin")Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

About the Nemvaleukin Clinical Development ProgramARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA(r) (pembrolizumab) in patients with advanced solid tumors. Ongoing trials in the ARTISTRY program include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7.

About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

KEYTRUDA(r) is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377For Media: Sourojit Bhowmick, Ph.D., +1 781 609 6397

View original content to download multimedia: https://www.prnewswire.com/news-releases/alkermes-to-present-data-on-nemvaleukin-alfa-at-the-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium-301461525.html

SOURCE Alkermes plc